摘要
目的评价米氮平治疗卒中后抑郁的疗效及安全性。方法将卒中后抑郁症患者58例随机分为2组。米氮平组(29例)和马普替林组(29例),治疗6周,采用汉密尔顿抑郁量表(HAMD)评定疗效,采用副反应量表(TESS)评定疗效和不良反应。结果米氮平组显效率为75.9%,马普替林组显效率72.4%,2组差异无统计学意义(P>0.05)。米氮平组显效时间早于马普替林组,米氮平组不良反应较少而轻微。结论米氮平是一种安全高效、耐受好、不良反应小、应用范围广的抗抑郁药,可作为脑卒中后抑郁的首选药物使用。
[ Objective ] To evaluate the efficacy and safety of mirtazapine in Treatment of post-stroke depression （PSD）. [ Methods ] Totally 58 Patients with PSD were randomly divided into mirtazapine group （29 cases） and maprotiline group （29 cases ） for 6 weeks treatment. Hamilton＇s depression scale （HAMD） and Emergent Symptom Scale （TESS） were used to assess the clinical efficacy and side effects. [ Results] The obvious effective rate of mirtazapine was 75.9% and that of maprotiline was 72.4%, the effective time of mirtazapine group was earlier than that of maprotiline group. Less and slight side effect was found in mirtazapine group. [ Condusion ] Mirtaznpine is a safe and effective antidepressants drug, with good toleration, less side effect and widely application, which earl be used as the first choice for treatment of PSD.
出处
《职业与健康》
CAS
2009年第23期2632-2633,共2页
Occupation and Health
关键词
卒中后抑郁
米氮平
马普替林
Post-stroke depression
Mirtazapine
Maprotiline
